STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Millions					1 Months Ended		3 Months Ended		6 Months Ended
	May 12, 2025 USD ($) d $ / shares shares	Apr. 08, 2024 shares	Mar. 26, 2024 $ / shares shares	Mar. 21, 2024 USD ($)	Jun. 30, 2025 USD ($) $ / shares shares	Aug. 31, 2020 USD ($)	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2024 $ / shares shares	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2024 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Consideration received on transaction \| $	$ 21.1			$ 21.9
Offering price of each common stock (in dollars per share) \| $ / shares					$ 0.75		$ 0.75		$ 0.75
Net of placement fees \| $	1.4			1.4
Proceeds from other offering expenses \| $	$ 0.5			$ 0.7
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock upon exercise of pre-funded warrants (in shares)		3,809,523			22,398,393		22,398,393	3,809,523	22,398,393	3,809,523
Pre-funded warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of new stock issued during the period (in shares)					34,398,393		34,398,393	3,809,523	34,398,393	3,809,523
Offering price of each common stock (in dollars per share) \| $ / shares								$ 1.00		$ 1.00
Stock price (in dollars per share) \| $ / shares					$ 0.01		$ 0.01	$ 0.01	$ 0.01	$ 0.01
Pre-Funded Warrants And Common Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding (in shares)					12,000,000		12,000,000		12,000,000
Direct offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	12,235,000		24,761,905
Cash placement fees				6.00%
Direct offering \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, number of shares issued in transaction, per unit (in shares)	1
Direct offering \| Common Stock And Common Warrant Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares	$ 0.50
Direct offering \| Pre-Funded Warrant And Common Warrant Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, price per share (in dollars per share) \| $ / shares	$ 0.49
Direct offering \| Common warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of new stock issued during the period (in shares)	46,633,393
Sale of stock, number of shares issued in transaction, per unit (in shares)			1
Number of shares of common stock for each Common warrant (in shares)	1		1
Sale of stock, price per share (in dollars per share) \| $ / shares			$ 0.84
Offering price of each common stock (in dollars per share) \| $ / shares	$ 0.75
Warrants exercisable, period after issuance	6 months		6 months
Term of warrants	5 years 6 months		5 years 6 months
Number of consecutive trading days where the weighted average stock price exceeds threshold \| d	10
Stock price weighted average threshold (in dollars per share) \| $ / shares	$ 2.75
Direct offering \| Pre-funded warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Sale of stock, number of shares issued in transaction (in shares)			28,571,428
Number of new stock issued during the period (in shares)	34,398,393		3,809,523
Number of shares of common stock for each Common warrant (in shares)			1
Sale of stock, price per share (in dollars per share) \| $ / shares			$ 0.83
Offering price of each common stock (in dollars per share) \| $ / shares	$ 0.01		1.00
Stock price (in dollars per share) \| $ / shares			$ 0.01
Jefferies LLC \| At-The-Market Offering Program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock offering program, maximum value \| $						$ 325.0
Stock offering program, remaining available amount \| $					$ 168.8		$ 168.8		$ 168.8
Issuance of common stock (in shares)							11,278,957	0	20,807,709	0
Consideration received on transaction \| $							$ 7.3		$ 17.6

SANGAMO THERAPEUTICS, INC 10-Q